Assessing Cardiac Function and Fluid Status with a Cardiac Scale: An Interview with John Lipman (CEO) and Corey Senten (Founder of Bodyport)

Bodyport, a San Francisco-based medical technology company, has developed the Bodyport Cardiac Scale, a series of scales that can non-invasively assess fluid status and cardiac function. The scale can detect these signals through the patient’s foot when they step into the device. The technology is meant to be convenient, takes only 20 seconds each morning, and should be easy to integrate into your daily life.

The device transmits data on cardiac hemodynamic parameters to clinicians via a cellular network and uses AI-based algorithms to identify various hemodynamic biomarkers to aid in early identification and diagnosis. . The system also incorporates a digital dashboard that allows medical staff to easily see trends in patient data over time.

med gadget I had the opportunity to speak with John Lipman, CEO of Bodyport, and Corey Centen, Founder, President and CTO of Bodyport, about technology and future plans.

Conn Hastings, Medgadget: Describe the importance of regular cardiac monitoring in enabling early intervention and limiting disease progression.

John Lippman, Bodyport: Regular cardiac monitoring allows early intervention to reduce disease exacerbation through timely and enhanced care. Cardiac monitoring is especially useful for people with advanced heart disease, such as heart failure. More than 6 million Americans have heart failure, about 1 million are hospitalized for heart failure annually, and 90% of his heart failure hospitalizations are due to worsening hemodynamic congestion.

These hospitalizations can be reduced or prevented by early detection of changes in cardiac function and fluid status along with optimized interventions.

We believe that long-term monitoring using the Cardiac Scale can have a significant impact on patient outcomes. Heart failure patients need to manage their condition on a daily basis for many years. To do this successfully, you need a solution that seamlessly integrates into your daily life. At Bodyport, we look forward to making a difference in patients’ lives with our commitment to generating robust clinical evidence demonstrating our ability to accurately detect heart failure events and detect them early from the comfort of a patient’s home. increase.*

Medgadget: Can you give us an overview of current technologies for measuring and monitoring cardiac hemodynamics and fluid status?

John Lipman: There are a number of technologies currently in use to remotely measure and monitor cardiac function and fluid status.

Weight monitoring and patient symptom assessment are standard care for detecting fluid retention in patients with worsening heart failure. However, weight gain is a late sign of worsening condition and usually does not provide sufficient advance warning to provide remote intervention that could prevent hospitalization.

Invasive devices, such as pulmonary artery pressure sensors, allow telemetry of clinical congestion and titration of heart failure therapy, but are hampered by the need for invasive procedures, relatively narrow patient indications, and high cost. , whose widespread use is limited. of transplant.

Wearable devices such as remote dielectric sensing and adhesive patches enable remote cardiac monitoring of lung fluid volume, electrocardiography, and physical activity, among others, but each has limitations and disrupts patients’ daily lives. Big changes need to be made.

Adhesive patches are limited by skin irritation, compliance, and are most useful for short-term (<30 days) monitoring.

There is a clear need for non-invasive, easy-to-use, affordable and scalable solutions, validated with rigorous clinical evidence for their efficacy. The Bodyport Cardiac Scale offers a convenient, accessible potential solution that requires patients to step on the scale daily. This is already very familiar behavior for patients and is part of standard heart failure care.

Medgadget: What inspired Bodyport to develop the Cardiac Scale? Have you identified the limitations of existing cardiac monitoring technology?

Cory Senten: Bodyport was founded by myself and Sarah Smith. Sarah Smith is an experienced inventor and entrepreneur with experience in the cardiology field, as well as his biomedical engineer.

The company’s mission is to enable everyone to live free from complex chronic illnesses by providing actionable insights from unique health signals gained through simple in-home experiences. . This mission began with the development of the Bodyport Cardiac Scale to keep heart failure patients healthy and out of hospital.

Unlike other cardiac monitoring technologies, the measurement takes just 20 seconds and does not require wearable devices or surgical implants, allowing the technology to be seamlessly integrated into the patient’s daily life.

Medgadget: What is the Bodyport Cardiac Scale and how does it work?

Cory Senten: Using advanced sensor technology and AI-powered algorithms, the Bodyport Cardiac Scale is designed to detect a wide range of hemodynamic biomarkers, well beyond what is currently available in consumer health technology. increase.

In one easy step, the Bodyport Cardiac Scale detects signals from a person’s foot and sends actionable data to the clinical care team.

Advanced sensors and proprietary algorithms non-invasively measure a wide range of hemodynamic biomarkers to assess cardiac function and fluid status. Clinical care teams receive alerts and insights into patient conditions, triage support, and take timely action.

Our first algorithm is the Bodyport Fluid Index. It is designed to more accurately reflect a patient’s fluid volume status, more effectively identifies fluid accumulation and deterioration, and is more accurate than traditional weight-based methods.

If a patient gains or loses weight, the body fluid index can provide context as to whether the weight is primarily due to fluid or another cause, such as changes in the patient’s clothing or body composition.

Medgadget: How does the scale communicate with medical staff? Can you give us an overview of the clinical dashboard and how it works?

John Lipman: Cardiac Scale uses a cellular network connection instead of Bluetooth or Wi-Fi to transmit measurement data. This feature simplifies the setup process and improves access to care for people without internet or smartphone access. This is a growing public health concern with the growth of telemedicine.

The Bodyport Clinical Dashboard allows clinical care teams to easily monitor patient data and health status changes over time within their existing workflows. The Fluid Index facilitates patient triage and enables timely and effective interventions.

Medgadget: How does the Cardiac Scale fit into a patient’s daily life?

John Lipman: Patients only need to spend about 20 seconds on a very familiar morning activity – getting on the scale. The Bodyport solution is designed to acquire hemodynamic signals via the Cardiac Scale and deliver optimized interventions for the patient. The solution is designed for seamless integration into the patient’s daily life as it does not require wearable devices or surgical implants.

We developed the Bodyport Patient Experience, an easy-to-use portal that combines helpful tools, resources, biomarker-based coaching, and more to help patients track their health, stay on treatment, and take action. Patients can get automatic reminders, check symptoms, and log medications and meals. See personalized health trends and insights. Access educational resources and disease-specific learning modules. Get one-on-one coaching and invite friends and family to support you.

Medgadget: Do you have any plans for additional medical technology? How do you see the company progressing in the next five years?

John Lipman: We plan to develop new biomarkers and algorithms to help more accurately predict worsening conditions in patients with complex chronic diseases. New biomarkers and algorithms will enable earlier and more accurate detection of adverse events, further enhancing our ability to keep patients in hospital and at home. These new algorithms also allow the technology to be extended to other cardio-renal diseases such as chronic kidney disease.

Link: Bodyport Home Page… Assessing Cardiac Function and Fluid Status with a Cardiac Scale: An Interview with John Lipman (CEO) and Corey Senten (Founder of Bodyport)

Back to top button